The AcT Trial: Tenecteplase vs Alteplase for Acute Ischemic Stroke
RebelEM
FEBRUARY 1, 2024
But, if a thrombolytic agent is to be given, tenecteplase would be a reasonable alternative to alteplase with similar efficacy, safety profile, and improved operational logistics. mg/kg, max 25mg) vs. intravenous alteplase (0.09 mg/kg followed by 0.81 vs Alteplase 34.8% Unadjusted risk difference 2.1% [ 95% CI -2.6 mg/kg followed by 0.81
Let's personalize your content